In direct compression campaigns on a 12-station rotary tablet press, the hygroscopic nature of the Shuanghuang Chuanku standardized extract powder is managed by maintaining granule moisture below 4.0% w/w and compression-suite relative humidity at ≤ 40% RH to prevent capping and punch filming. For companion-animal oral tablets, the API is typically incorporated at 25–45% w/w of the core weight, with microcrystalline cellulose at 20–35% w/w, lactose monohydrate at 15–25% w/w, crospovidone at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w; because published pre-formulation data for this specific extract powder in direct compression is limited, pilot-scale compression runs at 50,000–100,000 tablet batch size are required to establish acceptable ejection force and hardness profiles. Pre-compression blending in a 600 L bin blender at 12 rpm for 20 min is followed by in-process control of granule size by laser diffraction per ISO 13320:2020 for D10, D50, and D90 before tablet press start-up. Compliance references for the finished tablet include 21 CFR 211.65 for equipment construction, VICH GL18(R) for residual solvents, and Ph. Eur. 2.9.5 for uniformity of mass. Downstream production on a high-speed rotary press using 8–15 kN compaction force and 20–40 rpm turret speed produces tablets with hardness held at 60–90 N and friability at ≤ 0.8%. The terminal finished dosage type is a non-chewable oral tablet for companion animals, with engraved tooling to allow dose splitting. Operational boundaries include avoiding direct contact with hygroscopic excipients above 60% RH and pre-drying the API at 40–45°C for 2–3 h when initial moisture exceeds 6.0% w/w.

What governs sterile-filtration throughput for veterinary injectable solutions?

Clarified bulk solution of the Shuanghuang Chuanku API is prepared at 5–15% w/v in Water for Injection, passed through a 0.45 µm prefilter and then a 0.22 µm polyethersulfone membrane; throughput is governed by the polysaccharide fraction, which can reduce flux by 30–50% after 20–30 L/m² if the solution is not subjected to centrifugal clarification at 8,000–10,000 × g for 15 min. The downstream production process for injectable solutions includes pH adjustment to 5.5–7.0 with dilute hydrochloric acid or sodium hydroxide, addition of sodium chloride for isotonicity at 0.9% w/v, sterile filtration in an ISO 14644-1:2015 Class 5 aseptic filling suite, and filling into depyrogenated borosilicate glass vials. Filter integrity testing is performed by bubble point at ≤ 3.4 bar for the 0.22 µm membrane, and post-filtration hold time is limited to 4 h before filling to prevent microbial ingress in bulk solution. Industry compliance standards for this terminal injectable solution are Ph. Eur. 5.1.4 for sterility, 21 CFR 211.67 for equipment cleaning, and VICH GL18(R) for residual solvent control. The API addition ratio in the final injectable formulation is adjusted to deliver the target marker compound per millilitre; typical filling volumes range from 10 mL to 100 mL. Terminal finished dosage type is an injectable solution for intravenous or intramuscular administration in food-producing cattle and swine. Operational limitations include filter-membrane clogging by residual particulate below 1 µm, pyrogen control via LAL testing at ≤ 0.25 EU/mL, and incompatibility with polyvinyl chloride administration sets if the bulk solution contains surface-active solubilisers.

When roller-compacted granules replace wet-massed granulation for capsule filling

For equine hard-capsule production, wet granulation of the Shuanghuang Chuanku extract powder is avoided because elevated inlet drying temperatures above 60°C have been observed to reduce recovery of heat-sensitive flavonoid-glycoside markers in stability batches. The preferred downstream process is roller compaction at 20–30 bar roll pressure and 0.8–1.2 mm gap width, followed by oscillating sieving to a 20–40 mesh granule fraction. The API addition ratio in the encapsulated blend is 35–60% w/w, with lactose monohydrate at 20–35% w/w, crospovidone at 2–4% w/w, and sodium stearyl fumarate at 0.5–1.0% w/w; fill weights of 300–700 mg are processed on a dosator-type capsule machine at 10,000–20,000 capsules per hour. Capsule dissolution testing is performed per Ph. Eur. 2.9.3 using Apparatus II at 50 rpm in 900 mL phosphate buffer pH 6.8. Industry compliance references include Ph. Eur. 2.9.1 for disintegration and ISO 9001:2015 for quality management of the encapsulation line, with finished-product release testing per Ph. Eur. 2.9.5 for mass uniformity. Terminal finished dosage type is a hard gelatin capsule for equine oral administration. Field-scale data indicate that roller-compacted granules with compact hardness above 60 N can extend disintegration beyond 15 min, so process-transfer batches should be checked against the species-specific dissolution specification before releasing the line. The process is bounded by low granule fines below 15% to prevent capsule weight variability and by pre-drying the API at 45°C when storage relative humidity exceeds 60%.

Following geometric dilution of the Shuanghuang Chuanku API onto a calcium carbonate or corn-cob carrier in a horizontal ribbon blender, the resulting intermediate premix is filled into multi-wall paper sacks and intended for further dilution in complete poultry feed. The API addition ratio in the intermediate premix is 5–25% w/w; when diluted at 10 kg of intermediate premix per 1,000 kg of final feed, the complete feed contains 0.05–0.25% w/w of the standardized API, with the final therapeutic dose dictated by the veterinary prescription and active-marker concentration stated in the Certificate of Analysis. Downstream production includes pre-blending at 10 rpm for 10 min, followed by final mixing in a twin-shaft paddle mixer for 3–5 min and pelleting at conditioning temperatures not exceeding 70°C to avoid thermal losses. Homogeneity is verified by sampling 10 points per blender using HPLC marker assay with acceptance ±5% relative standard deviation. Industry compliance standards for the medicated feed premix include GMP+ B2, EU Regulation 2019/4 on medicated feed, and 21 CFR 225 where applicable for export. The terminal finished dosage type is a dry powder premix for poultry feed. Operational boundaries include avoiding contact with acidic molasses-based binders that can promote clumping and segregation, and ensuring the carrier moisture is below 12% w/w before mixing to prevent caking during storage.

Water-soluble granule extrusion parameters for swine drinking-water medication

Granulation of the Shuanghuang Chuanku API for swine drinking-water use is performed by fluid-bed spray granulation rather than high-shear wet granulation to preserve water dispersibility. The API addition ratio is 10–30% w/w in a matrix of lactose monohydrate at 40–60% w/w, sorbitol at 10–20% w/w, and povidone K30 at 2–4% w/w as binder. Inlet air temperature is held at 50–65°C, spray rate at 50–100 g/min, and product moisture at ≤ 2.5% w/w; the dried granules are sieved to 0.5–1.0 mm and filled into laminated foil pouches under ≤ 30% RH. Granule bulk density is held at 0.45–0.60 g/mL to ensure automatic pouch filling. Industry compliance for the finished granules references 21 CFR 210/211 for finished pharmaceuticals, Ph. Eur. 2.9.35 for powder flow, and ISO 13320:2020 for laser-diffraction particle size analysis. The terminal finished dosage type is a water-soluble granule for reconstitution in swine drinking-water lines at 0.5–2 g/L. Field-scale observations from nipple-drinker systems indicate that residual polysaccharide viscosity can increase line pressure when the stock solution exceeds 5 g/L; therefore aeration or anti-caking silicon dioxide at 0.5–1.0% w/w is used to maintain nozzle flow. Avoid combining the granules with hard water containing calcium above 250 mg/L without a chelating agent, as flavonoid-metal complexes may precipitate and reduce bioavailability.

Poultry drinking-water solution stability against biofilm recontamination

For concentrated oral solutions, the Shuanghuang Chuanku API is dissolved or suspended in purified water at 2–10% w/v with buffering to pH 5.0–6.5, and preserved with a blend of sodium benzoate at 0.1–0.2% w/v and potassium sorbate at 0.1–0.2% w/v unless stability screening shows precipitation with polyphenolic fractions. The downstream production process includes high-shear dispersion at 10,000–15,000 rpm for 10–15 min, filtration through a 10 µm depth filter, pasteurization at 70°C for 30 min, and aseptic filling into high-density polyethylene containers with light-resistant overpackaging. Container closure integrity is verified by vacuum decay per ASTM F2338-09. Industry compliance references include Ph. Eur. 5.1.3 for efficacy of antimicrobial preservation, 21 CFR 211.67 for equipment cleaning, and VICH GL18(R) for residual solvents. The terminal finished dosage type is an oral solution for flock administration through proportioning medicators at final dilution ratios of 1:1000 to 1:5000 in drinking water. Operational limitations include avoiding quaternary ammonium preservatives at concentrations above 0.02% w/v due to incompatibility with anionic herbal tannins, and protecting the bulk product from UV light to prevent photodegradation of marker compounds during storage beyond 12 months at 25°C.